🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Encompass Health sets quarterly dividend at $0.17 per share

Published 10/17/2024, 10:04 PM
EHC
-

BIRMINGHAM, Ala. - Encompass Health Corporation (NYSE:EHC) has declared a quarterly cash dividend for its common stock shareholders. The company announced today that a dividend of $0.17 per share will be paid on January 15, 2025, to stockholders of record as of January 2, 2025.

Encompass Health, recognized as a leader in the field of rehabilitative care, operates 165 hospitals across 38 states and Puerto Rico. The company is known for employing advanced technology and innovative treatments to provide high-quality care for patients recovering from major injuries or illnesses.

The declaration of dividends is a common practice for Encompass Health, which has consistently provided returns to its shareholders. This latest dividend announcement is in line with the company's history of sharing profits with its investors.

The forward-looking statements in the press release indicate that while the company has announced the timing and amount of the dividend, these are subject to change based on various factors. These factors include, but are not limited to, changes in federal, state, and local regulations, economic and capital market conditions, and the company's ability to maintain compliance with healthcare industry regulations.

Investors and shareholders are reminded that forward-looking statements are not guarantees of future performance and involve risks and uncertainties. Actual results may differ materially from those projected due to numerous factors that could affect the company's operations and financial outcomes.

The information provided in this news article is based on a press release statement from Encompass Health Corporation.

In other recent news, Encompass Health Corp. demonstrated robust growth in its Q2 revenue and adjusted EBITDA, which increased by 9.6% and 8.9% respectively. The company also announced the addition of 194 beds and plans to open two new hospitals. KeyBanc initiated coverage on the healthcare provider with an Overweight rating and a price target of $115.00, highlighting the company's dominant position within the Inpatient Rehabilitation Facility (IRF) industry.

RBC Capital maintained an Outperform rating for Encompass Health, raising the stock's price target to $105 from $95, following a review of the company's Q2 performance and updated guidance. The firm's revised valuation model took into account these recent developments. Moody's (NYSE:MCO) also upgraded the company's ratings, reflecting positively on its performance.

Despite potential challenges such as increased bad debt due to medical necessity claim review audits and potential volatility in provider tax revenue, Encompass Health remains optimistic about its future, planning expansions into new geographies including Rhode Island and Connecticut. These are the latest developments in the company's ongoing efforts to navigate the competitive landscape effectively.

InvestingPro Insights

Encompass Health Corporation's recent dividend announcement aligns with its strong financial performance and shareholder-friendly policies. According to InvestingPro data, the company's dividend yield stands at 0.7%, with a notable dividend growth of 13.33% over the last twelve months as of Q2 2024. This increase in dividends reflects the company's robust financial health and commitment to rewarding shareholders.

The company's solid financial position is further underscored by its impressive revenue growth of 10.86% over the last twelve months as of Q2 2024, reaching $5,070.9 million. This growth is complemented by a healthy gross profit margin of 41.32% for the same period, indicating efficient cost management and strong pricing power in the rehabilitative care sector.

InvestingPro Tips highlight that Encompass Health is trading near its 52-week high, with a remarkable 51.56% price total return over the past year. This performance suggests strong investor confidence in the company's business model and growth prospects. Additionally, the company's P/E ratio of 24.5 is considered low relative to its near-term earnings growth, potentially indicating an attractive valuation for investors.

For those interested in a deeper analysis, InvestingPro offers 7 additional tips for Encompass Health, providing valuable insights for investors looking to make informed decisions about this healthcare leader.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.